March 10 (Reuters) -
BioNTech SE <22UAy.DE>::
*EXPECTS 2025 TOTAL REVENUES BETWEEN EUR 1.7 BILLION AND EUR 2.2 BILLION
*CASH AND CASH EQUIVALENTS PLUS SECURITY INVESTMENTS OF EUR 17.4 BILLION AS OF DECEMBER 31, 2024
*CEO - EXPECT 2025 TO BE A DATA-RICH YEAR WITH MULTIPLE IMPORTANT UPDATES FROM OUR PRIORITY PROGRAMS, WHICH WE BELIEVE HAVE DISRUPTIVE POTENTIAL AND COULD IMPROVE STANDARD OF CARE, IF SUCCESSFULLY DEVELOPED AND APPROVED
*OUTLOOK 2025: RESEARCH AND DEVELOPMENT EXPENSES EUR 2,600 MILLION - EUR 2,800 MILLION, SG&A EXPENSES EUR 650 MILLION - EUR 750 MILLION
*OUTLOOK 2025: CAPITAL EXPENDITURES FOR OPERATING ACTIVITIES EUR 250 MILLION - EUR 350 MILLION
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 10-MAR-202510:55:00.233 GMT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.